Dear Participants,

On behalf of the BioRN Cluster and the SMART HUB Flemish Brabant, we would like to welcome you all to the first Health Axis Europe Visionary Seminar in Heidelberg.

Visionary Seminars zoom in on fast evolutions in health, ICT, biotech, nanotech, materials, food and related domains. The events aim to depict a vision on the state of the art technologies that will start to pay off in the coming generations and where concrete applications are expected within 5, 10 to 15 years.

Heidelberg and Leuven, as two major players in the field world-wide, jointly organize the Health Axis Europe Visionary Seminar on Precision Oncology.

While some of the most promising novel scientific approaches from renowned Flemish and German research groups in industry and academia will be depicted, the event will also look into the economic hindrances theses advancements of precision medicine are facing before they can enter routine clinical practice.

Eminent speakers will discuss reimbursement challenges and policies and cost-based pricing versus value-based pricing from a pharma, payer and molecular diagnostics perspective.

Visionary Greetings,

Dr. Gitte Neubauer, Chair of BioRN Network e.V. Executive Board

Marc Florquin, Vice-Governor for Economy, Province of Flemish Brabant
Tom Dehaene, Vice-Governor for

Internationalisation, Province of Flemish Brabant





Partners:















Sponsors:







www.biorn.org



Health Axis Europe Visionary Seminar Heidelberg - Leuven







Diether Lambrechts

Co-director VIB-KULeuven Center for Cancer Biology and Head of the Laboratory for Translational Genetics



Andree Blaukat

Global Head of the TIP Oncology at Merck Serono



Olaf Witt

Director of Hopp Children's Cancer Center at the NCT Heidelberg (KiTZ)



Liesbeth Lagae

Program Director Life Science Technologies at IMEC



Chair of Ci3 Cluster e.V.



4.00 pm	Welcome address by Stefan Meuer
4.10 pm	Innovative diagnostic and therapeutic approaches

Diether Lambrechts

Single Cell sequencing of the tumor microenvironment

Andree Blaukat

The rollercoaster ride of the c-Met inhibitor Tepotinib - a real-life example for precision medicine

Olaf Witt

Precision Medicine in Pediatric Oncology – the INFORM program

Liesbet Lagae

Liquid biopsies go digital - chip based tools to capture and inspect circulating tumor cells

Özlem Türeci

Individualized Cancer Immunotherapy

6.00 pm	Networking and finger food
6.30 pm	Social and economic impact of novel treatment options – Panel Discussion

Frank Ulrich Montgomery, President of the German Medical Association

Katelijne De Nys, Chair Belgian Commission for the Reimbursement of Medicines

Michel Delforge, Chairman of the Leuven Cancer Institute

Michael Schlander, German Cancer Research Center (DKFZ), Health Economics

7.30 pm Closing Remarks

Moderated by Gerard Drewes, BioRN Network e.V.

Frank Ulrich Montgomery

President of the German Medical Association



Katelijne De Nys

Chair of the Belgian Commission for the Reimbursement of Medicines and professor at the KU Leuven



Michel Delforge

Chairman of the Leuven
Cancer Institute



Michael Schlander

Head of health economics division at the German Cancer Research Center





Gerard Drewes
BioRN Network e.V. Scientific Board
Cellzome. a GSK company



Stefan Meuer
Director Institute for Immunology
Heidelberg University